Evidence map›Paper›PMID 32333641›Full record

Trial reportPharmacology research & perspectives2020

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta

Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Chris WynneChristchurch Clinical Studies Trust Ltd, Christchurch, New Zealand.
Christian SchwabeAuckland Clinical Studies Ltd, Auckland, New Zealand.
Emmanuelle VincentFresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.
Armin SchuelerBiostatistics, Merck Healthcare, Darmstadt, Germany.
Janka RydingSVAR Life Science - Wieslab AB, Lund, Sweden.
Martin UllmannFresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.ORCID 0000-0002-3088-3209
Vishal GhoriFresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.
Radmila KancevaFresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.
Michael StahlFresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.ORCID 0000-0002-7171-9691
Auckland Institute of Studies · NZChristchurch Clinical Studies Trust · NZMerck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta

Indexed as

AdultAntibodiesBiosimilar PharmaceuticalsDouble-Blind MethodFemaleFilgrastimHealthy VolunteersHumansMalePolyethylene GlycolsYoung AdultAntibodiesBiosimilar PharmaceuticalsFilgrastimpegfilgrastimPolyethylene Glycolsantidrug antibodiesimmunogenicityMSB11455pegfilgrastimsafetytolerability

Identifiers

PMID32333641
PMCPMC7183238
OpenAlexW3020175599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.